Doubts on ChemoCentryx’s diabetic nephropathy study trigger plunge

John Carroll Shares of ChemoCentryx tanked this morning after the biotech released weak interim results for its mid-stage study on a new drug for diabetic nephropathy.  FierceBiotech ...

Debiopharm Group initiates phase I dose escalation study

barbara.lempert With Debio 1347 (CH5183284) in advanced solid tumors with FGFR alterations Lausanne, Switzerland – September 2nd, 2013 – Debiopharm Group™ (Debiopharm), the ...

Study: Biogen hemophilia drugs will allow market to thrive

mia.burns By Mia Burns (mia.burns@ubm.com) Eloctate and Alprolix, Biogen Idec’s hemophilia drug candidates, are positioned to capture a significant share of the hemophilia market ...

Roche’s gRED sees promising results in PhII macular degeneration study

John Carroll Investigators say that lampalizumab slowed progression of AMD in patients with advanced disease, shrinking the area of geographic atrophy by 20.4%. AMD is a leading cause ...

Argos turns to unusual players for $42.5M needed to fund PhIII cancer study

John Carroll With a Phase III cancer immunotherapy study under way, Durham, NC-based Argos Therapeutics today put in place its fifth fundraising, banking $ 42.5 million from a big ...

Rigel shares slide after another drug flops in PhII asthma study

John Carroll Shares of Rigel Pharmaceuticals took a dive this morning, dropping 17% after the South San Francisco-based biotech announced that it is burying a program for allergic asthma ...

Pharma study shows drop in Q2 deal activity

Ryan McBride After some heavy deal flow in the first three months of 2013, the second quarter showed a 40% slide in deal volume compared with the previous one. FierceBiotech News

Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study

barbara.lempert Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC   —  Encouraging results from the first proof-of-concept ...

In-depth study examines impact of e-prescribing

mia.burns By Mia Burns As e-prescribing adoption continues to increase among physicians, the practice presents challenges and opportunities for pharma companies. Management and technology ...

Study: No Link Between Faster Drug Approvals, Safety Warnings

barbara.lempert No link between faster drug approvals, regulatory safety warnings and drug withdrawals in Canada and the USA. TORONTO, Aug. 14, 2013 /CNW/ – Faster drug ...

Study: Anxiety Medication Use Higher Among Caregivers

barbara.lempert New Study Finds Anxiety Medication Use Higher Among Caregivers Express Scripts Data Reveal 29% Greater Use of Anxiety Medications, Higher Prevalence of Other Stress-Related ...

Cyclacel’s Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid Arthritis

barbara.lempert     Study Supported by Approximately $ 1.5 Million Grant From UK                      Medical Research Council BERKELEY HEIGHTS, N.J. and ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS